JP2014043462A5 - - Google Patents

Download PDF

Info

Publication number
JP2014043462A5
JP2014043462A5 JP2013244692A JP2013244692A JP2014043462A5 JP 2014043462 A5 JP2014043462 A5 JP 2014043462A5 JP 2013244692 A JP2013244692 A JP 2013244692A JP 2013244692 A JP2013244692 A JP 2013244692A JP 2014043462 A5 JP2014043462 A5 JP 2014043462A5
Authority
JP
Japan
Prior art keywords
group
carbon atoms
amino
nucleic acid
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013244692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014043462A (ja
JP5669073B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2013244692A priority Critical patent/JP5669073B2/ja
Priority claimed from JP2013244692A external-priority patent/JP5669073B2/ja
Publication of JP2014043462A publication Critical patent/JP2014043462A/ja
Publication of JP2014043462A5 publication Critical patent/JP2014043462A5/ja
Application granted granted Critical
Publication of JP5669073B2 publication Critical patent/JP5669073B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013244692A 2009-10-29 2013-11-27 架橋型人工ヌクレオシドおよびヌクレオチド Active JP5669073B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013244692A JP5669073B2 (ja) 2009-10-29 2013-11-27 架橋型人工ヌクレオシドおよびヌクレオチド

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2009248979 2009-10-29
JP2009248979 2009-10-29
JP2010023209 2010-02-04
JP2010023209 2010-02-04
JP2013244692A JP5669073B2 (ja) 2009-10-29 2013-11-27 架橋型人工ヌクレオシドおよびヌクレオチド

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011538366A Division JPWO2011052436A1 (ja) 2009-10-29 2010-10-19 架橋型人工ヌクレオシドおよびヌクレオチド

Publications (3)

Publication Number Publication Date
JP2014043462A JP2014043462A (ja) 2014-03-13
JP2014043462A5 true JP2014043462A5 (cg-RX-API-DMAC7.html) 2014-05-29
JP5669073B2 JP5669073B2 (ja) 2015-02-12

Family

ID=43921860

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011538366A Ceased JPWO2011052436A1 (ja) 2009-10-29 2010-10-19 架橋型人工ヌクレオシドおよびヌクレオチド
JP2013244692A Active JP5669073B2 (ja) 2009-10-29 2013-11-27 架橋型人工ヌクレオシドおよびヌクレオチド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011538366A Ceased JPWO2011052436A1 (ja) 2009-10-29 2010-10-19 架橋型人工ヌクレオシドおよびヌクレオチド

Country Status (7)

Country Link
US (1) US8541562B2 (cg-RX-API-DMAC7.html)
EP (1) EP2495248B1 (cg-RX-API-DMAC7.html)
JP (2) JPWO2011052436A1 (cg-RX-API-DMAC7.html)
CN (1) CN102596983B (cg-RX-API-DMAC7.html)
AU (1) AU2010312751B2 (cg-RX-API-DMAC7.html)
CA (1) CA2778171C (cg-RX-API-DMAC7.html)
WO (1) WO2011052436A1 (cg-RX-API-DMAC7.html)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127280B2 (en) 2010-08-31 2015-09-08 Osaka University Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient
EP2792746A4 (en) 2011-12-12 2015-09-16 Nat Cerebral & Cardiovascular Ct OLIGONUCLEOTIDE AND THERAPEUTIC FOR HYPERLIPIDEMIA WITH THIS AS AN ACTIVE SUBSTANCE
EP2862868B1 (en) * 2012-06-18 2020-04-08 Daiichi Sankyo Company, Limited Intermediate for production of nucleoside analogue, and method for producing same
KR101707437B1 (ko) 2012-09-21 2017-02-16 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 구아니딘 가교를 갖는 인공 뉴클레오시드 및 올리고뉴클레오티드
WO2014109384A1 (ja) * 2013-01-10 2014-07-17 塩野義製薬株式会社 架橋型核酸誘導体の製造方法
US20150337002A1 (en) * 2013-01-15 2015-11-26 Shionogi & Co., Ltd. Nucleoside and nucleotide having sulfonamide structure
WO2014126229A1 (ja) 2013-02-18 2014-08-21 塩野義製薬株式会社 含窒素複素環構造を有するヌクレオシド及びヌクレオチド
WO2015020194A1 (ja) * 2013-08-09 2015-02-12 国立大学法人大阪大学 Ａｃｓｌ１に対するアンチセンスオリゴヌクレオチド
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
JP6722586B2 (ja) * 2014-07-10 2020-07-15 賢二 中野 アンチセンス抗悪性腫瘍剤
AU2015327836B2 (en) 2014-10-03 2021-07-01 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
JP2018140938A (ja) * 2015-07-24 2018-09-13 日産化学株式会社 人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド
TW201718618A (zh) * 2015-09-18 2017-06-01 田邊三菱製藥股份有限公司 架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物
CN108603230A (zh) 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2017119463A1 (ja) * 2016-01-07 2017-07-13 国立大学法人大阪大学 α－シヌクレイン発現抑制剤
WO2017131124A1 (ja) 2016-01-26 2017-08-03 日産化学工業株式会社 一本鎖オリゴヌクレオチド
EP3418289B1 (en) 2016-02-17 2026-04-08 Institute Of Science Tokyo Artificial nucleoside and artificial nucleotide, and artificial oligonucleotide
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
JP2020055750A (ja) * 2017-01-30 2020-04-09 賢二 中野 癌浸潤または転移阻害核酸薬
AU2018215440B2 (en) 2017-02-06 2024-10-24 Nissan Chemical Corporation Single-stranded oligonucleotide
EP3587576A4 (en) 2017-02-21 2021-01-06 Osaka University ANTISENSE OLIGONUCLEIC ACID
US11286275B2 (en) 2017-02-21 2022-03-29 Osaka University Nucleic acid compound and oligonucleotide
EP3603648B1 (en) 2017-03-29 2025-09-17 Shionogi & Co., Ltd Complex of nucleic acid medicine and multibranched lipid
JP7141621B2 (ja) 2017-03-31 2022-09-26 学校法人 愛知医科大学 コンドロイチン硫酸生合成を阻害するアンチセンス核酸
US11273222B2 (en) 2017-05-26 2022-03-15 National Cerebral And Cardiovascular Center Antisense nucleic acid targeting PCSK9
WO2019009298A1 (ja) * 2017-07-05 2019-01-10 国立大学法人大阪大学 α－シヌクレイン発現抑制剤
WO2019009299A1 (ja) 2017-07-05 2019-01-10 国立大学法人大阪大学 α－シヌクレイン発現抑制するＥＮＡアンチセンスオリゴヌクレオチド
BR112020001430A2 (pt) 2017-07-26 2020-07-28 Nissan Chemical Corporation oligonucleotídeo de fita simples
KR102318434B1 (ko) 2017-08-25 2021-11-01 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
IL272864B2 (en) 2017-08-31 2024-03-01 Mitsubishi Tanabe Pharma Corp Il-33 antagonist-containing therapeutic agent for endometriosis
BR112020018902A2 (pt) 2018-03-20 2021-01-26 Tokyo Institute Of Technology oligonucleotídeo antissenso com toxicidade reduzida
CA3099280A1 (en) 2018-05-04 2019-11-07 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
JP7473113B2 (ja) * 2018-07-31 2024-04-23 国立大学法人大阪大学 オリゴヌクレオチドを含有する小細胞肺癌治療薬
AU2020227825B2 (en) 2019-02-27 2026-03-26 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
WO2020203896A1 (ja) 2019-03-29 2020-10-08 シスメックス株式会社 新規人工核酸、その製造方法及び用途
SG11202112741XA (en) 2019-05-31 2021-12-30 Aligos Therapeutics Inc Modified gapmer oligonucleotides and methods of use
JP7692829B2 (ja) 2019-07-30 2025-06-16 塩野義製薬株式会社 Ｍｕｒｆ１を標的とする核酸医薬
US20220282248A1 (en) 2019-08-27 2022-09-08 National University Corporation Tokai National Higher Education And Research System Molecular targeted nucleic acid medicine for gastric cancer
WO2021127406A1 (en) * 2019-12-19 2021-06-24 The Regents Of The University Of California Methods of producing target capture nucleic acids
WO2021132648A1 (ja) * 2019-12-27 2021-07-01 ルクサナバイオテク株式会社 Ｒｅｃｑｌの発現を阻害するアンチセンスオリゴヌクレオチド及びその用途
WO2021177267A1 (ja) 2020-03-02 2021-09-10 田辺三菱製薬株式会社 ｍｉＲ－３３ｂ阻害物質による動脈瘤の予防または治療
US20230113556A1 (en) 2020-03-26 2023-04-13 National Cerebral And Cardiovascular Center Antisense nucleic acid targeting apoc3
CN115916262A (zh) 2020-04-21 2023-04-04 旗舰创业股份有限公司 双官能分子及其使用方法
CN115867657A (zh) 2020-05-11 2023-03-28 斯托克制药公司 用于治疗疾患和疾病的opa1反义寡聚物
CN116322706B (zh) 2020-09-25 2025-12-05 株式会社理真思 新人工核酸、其制造方法和用途
CN116507727A (zh) 2020-11-06 2023-07-28 住友制药株式会社 Rps25基因的表达和/或功能调节剂
US20240148775A1 (en) 2021-02-25 2024-05-09 Osaka University Oligonucleotide for inducing n-exon skipping during rest mrna precursor processing
EP4331606A4 (en) 2021-04-30 2025-05-07 Kyoto University PREVENTION OR TREATMENT OF MYOPATHY USING A MIR-33B INHIBITOR
US20240247263A1 (en) 2021-05-06 2024-07-25 Luxna Biotech Co., Ltd. Method for designing oligonucleotide having reduced central toxicity
TW202313975A (zh) 2021-05-28 2023-04-01 日商住友製藥股份有限公司 反義核酸
US20240390508A1 (en) 2021-08-21 2024-11-28 Takeda Pharmaceutical Company Limited Human transferrin receptor binding peptide-drug conjugate
EP4458836A4 (en) 2021-12-27 2025-05-21 Riken Genesis Co., Ltd. Novel artificial nucleic acid, method for producing same, and use of same
EP4495242A1 (en) 2022-03-17 2025-01-22 Aichi Medical University Antisense nucleic acid capable of inhibiting biosynthesis of chondroitin sulfate
WO2024101446A1 (ja) 2022-11-10 2024-05-16 ルクサナバイオテク株式会社 架橋部にグアニジノ構造を有する修飾ヌクレオシドおよびそれを用いたオリゴヌクレオチドの製造方法
JPWO2024181416A1 (cg-RX-API-DMAC7.html) 2023-02-28 2024-09-06
JPWO2024257847A1 (cg-RX-API-DMAC7.html) 2023-06-16 2024-12-19
JPWO2025005265A1 (cg-RX-API-DMAC7.html) * 2023-06-30 2025-01-02
US20250368996A1 (en) 2024-05-14 2025-12-04 Aligos Therapeutics, Inc. Modified antisense oligonucleotides for treating hepatitis b virus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
JP2002516256A (ja) 1998-05-26 2002-06-04 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド 二環式糖成分を有する新規ヌクレオシド
EP1481983A4 (en) 2002-02-13 2008-04-02 Takeshi Imanishi NUCLEOSIDE ANALOGUE AND OLIGONUCLEOTIDE DERIVATIVES CONTAINING A NUCLEOTIDE ANALOGON THEREOF
EP1661905B9 (en) * 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
US9127280B2 (en) * 2010-08-31 2015-09-08 Osaka University Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient

Similar Documents

Publication Publication Date Title
JP2014043462A5 (cg-RX-API-DMAC7.html)
JP2013535220A5 (cg-RX-API-DMAC7.html)
RU2015126856A (ru) Дисульфидные маскированные пролекарственные композиции и способы
JP2016501520A5 (cg-RX-API-DMAC7.html)
JP2019512478A5 (cg-RX-API-DMAC7.html)
JP2017119663A5 (cg-RX-API-DMAC7.html)
JP2016503300A5 (cg-RX-API-DMAC7.html)
EP4458348A3 (en) Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
JP2012140458A5 (cg-RX-API-DMAC7.html)
JP2013102146A5 (ja) 化合物
JP2009504669A5 (cg-RX-API-DMAC7.html)
NZ593712A (en) Intermediates for synthesising nucleoside aryl phosphoramidates
JP2018504379A5 (cg-RX-API-DMAC7.html)
JP2010235633A5 (cg-RX-API-DMAC7.html)
JP2018519343A5 (cg-RX-API-DMAC7.html)
JP2014526533A5 (cg-RX-API-DMAC7.html)
JP2012140436A5 (ja) 物質
WO2014078295A8 (en) Gemcitabine prodrugs and uses thereof
JP2013010731A5 (ja) 複素環化合物
JP2013532122A5 (cg-RX-API-DMAC7.html)
JP2009504772A5 (cg-RX-API-DMAC7.html)
JP2010515731A5 (cg-RX-API-DMAC7.html)
CY1114318T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
JP2017511321A5 (cg-RX-API-DMAC7.html)
EP3388426A3 (en) Compounds for protection of cells